Capital International Ltd. CA Sells 25,675 Shares of Vertex Pharmaceuticals Incorporated $VRTX

Capital International Ltd. CA decreased its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 21.2% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 95,612 shares of the pharmaceutical company’s stock after selling 25,675 shares during the period. Vertex Pharmaceuticals comprises approximately 1.5% of Capital International Ltd. CA’s investment portfolio, making the stock its 12th biggest holding. Capital International Ltd. CA’s holdings in Vertex Pharmaceuticals were worth $43,347,000 as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. Colonial Trust Co SC raised its stake in Vertex Pharmaceuticals by 118.8% in the third quarter. Colonial Trust Co SC now owns 70 shares of the pharmaceutical company’s stock worth $27,000 after buying an additional 38 shares in the last quarter. Eagle Bay Advisors LLC bought a new position in Vertex Pharmaceuticals in the fourth quarter worth approximately $29,000. IMG Wealth Management Inc. raised its stake in Vertex Pharmaceuticals by 277.8% in the fourth quarter. IMG Wealth Management Inc. now owns 68 shares of the pharmaceutical company’s stock worth $31,000 after buying an additional 50 shares in the last quarter. Ares Financial Consulting LLC bought a new position in Vertex Pharmaceuticals in the fourth quarter worth approximately $33,000. Finally, Archer Investment Corp raised its stake in Vertex Pharmaceuticals by 89.7% in the fourth quarter. Archer Investment Corp now owns 74 shares of the pharmaceutical company’s stock worth $34,000 after buying an additional 35 shares in the last quarter. Institutional investors own 90.96% of the company’s stock.

Insider Buying and Selling at Vertex Pharmaceuticals

In other Vertex Pharmaceuticals news, Director Sangeeta N. Bhatia sold 318 shares of the company’s stock in a transaction on Monday, May 4th. The shares were sold at an average price of $423.73, for a total value of $134,746.14. Following the sale, the director directly owned 4,924 shares of the company’s stock, valued at approximately $2,086,446.52. This represents a 6.07% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CMO Carmen Bozic sold 6,988 shares of the company’s stock in a transaction on Tuesday, May 12th. The shares were sold at an average price of $450.00, for a total transaction of $3,144,600.00. Following the completion of the sale, the chief marketing officer directly owned 26,088 shares in the company, valued at approximately $11,739,600. The trade was a 21.13% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 11,717 shares of company stock valued at $5,309,945. 0.20% of the stock is owned by insiders.

Vertex Pharmaceuticals Price Performance

Shares of VRTX opened at $446.83 on Friday. The firm has a market capitalization of $113.41 billion, a PE ratio of 26.50, a price-to-earnings-growth ratio of 1.91 and a beta of 0.30. Vertex Pharmaceuticals Incorporated has a 1-year low of $362.50 and a 1-year high of $507.92. The company’s fifty day moving average price is $437.33 and its 200-day moving average price is $451.81.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its quarterly earnings data on Monday, May 4th. The pharmaceutical company reported $4.47 earnings per share for the quarter, beating analysts’ consensus estimates of $4.24 by $0.23. Vertex Pharmaceuticals had a net margin of 35.51% and a return on equity of 23.86%. The firm had revenue of $2.99 billion for the quarter, compared to analyst estimates of $2.99 billion. During the same period in the previous year, the company earned $4.06 earnings per share. The business’s quarterly revenue was up 8.3% compared to the same quarter last year. As a group, research analysts anticipate that Vertex Pharmaceuticals Incorporated will post 17.02 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on VRTX shares. Royal Bank Of Canada lifted their price target on shares of Vertex Pharmaceuticals from $541.00 to $543.00 and gave the stock an “outperform” rating in a report on Tuesday, May 5th. Sanford C. Bernstein cut their price target on shares of Vertex Pharmaceuticals from $577.00 to $572.00 and set an “outperform” rating on the stock in a report on Tuesday, May 5th. Stifel Nicolaus lifted their price target on shares of Vertex Pharmaceuticals from $445.00 to $466.00 and gave the stock a “hold” rating in a report on Friday, February 13th. Morgan Stanley lifted their price target on shares of Vertex Pharmaceuticals from $612.00 to $616.00 and gave the stock an “overweight” rating in a report on Tuesday, May 5th. Finally, Maxim Group raised shares of Vertex Pharmaceuticals from a “hold” rating to a “buy” rating and set a $575.00 price target on the stock in a report on Wednesday, March 18th. Twenty-two analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $555.91.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex’s marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.